Efficacy And Safety Of The Anti-Epidermal Growth Factor Antibody (EGFR) IMC-C225, In Combination With Cisplatin In Patients With Recurrent Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Refractory To Cisplatin Containing Chemotherapy

Diana Stripp, MD

University of Pennsylvania Cancer
Last Modified: May 13, 2001

Share article


Presenter: Waun Ki Hong/Roy S. Herbst
Affiliation: Anderson Cancer Center

Background:

  • Patients with recurrent SCCHN who fail to respond to platinum-based therapy rarely respond to second-line treatment
  • This study was performed to evaluate IMC-C225 in patients that have failed standard chemotherapy.

Materials and Methods:

  • Patients (pts) with recurrent SCCHN received 2 cycles of a cisplatin (CDDP) containing regimen.
  • Those with either progressive or stable disease went on to receive CDDP + IMC-C225 (41 patients).
  • Pts received IMC-C225, 400 mg/m2 loading dose followed by 250 mg/m2, weekly, plus intravenous cDDP at the same dose and schedule previously administered.
  • This study only addresses the 41 patients with stable disease who went on to receive CDDP+IMC-C225

Results:

  • Seventy-five percent of the patients were male, the mean age was 54.4 years (range 39-76 years)
  • The most commonly reported adverse events related to IMC-C225 therapy were folliculitis/acne and allergic reactions (5%).
  • Ten (24%) patients achieved an objective response to therapy (one complete response and nine partial responses), and 25 (61%) patients maintained stable disease.
  • The trial for the progressive disease subgroup is still ongoing and will be presented at a future time.

Authors' Conclusions

  • IMC-C225 in combination with CDDP appears to be well tolerated and the response rate suggests clinical activity for this combination of biologic and cytotoxic therapy.
  • IMC-C225 has potential for treatment of all advanced stage of disease

Clinical/Scientific Implications:

  • In analyses of the 22 pts with progression of disease after the induction chemotherapy regimen which were not reported in the abstract, it was reported 23% achieved an objective response to therapy.
  • This is a promising molecular targeting strategy that has potential to become and important avenue for cancer treatment in the future.

ASCO Abstract 895

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen


News
Improves progression-free survival in those with recurrent or metastatic squamous-cell disease

Mar 9, 2011 - Zalutumumab, a human IgG1 monoclonal antibody targeting the epidermal growth factor receptor, appears to significantly prolong progression-free survival in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy, according to a study published online March 7 in The Lancet Oncology.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More